Leaders in the field of neuroendocrine tumors offer insights in this moderated series. The healthcare professionals in this podcast are paid consultants for Ipsen. Each episode features insights on diagnosis, treatment for certain types of NETs, and more. This content is intended for US healthcare providers only. Find out more about a treatment option at TreatingNETs.com.
A Multidisciplinary Approach to NETs
Dr. Robert Ramirez, a member of the American Society of Clinical Oncology (ASCO), and NET nurse navigator Pam Ryan discuss the importance of the multidisciplinary team, building trust, and creating positive treatment experiences for patients with gastrointestinal and pancreatic NETs (GEP-NETs).
(c) 2020 Ipsen Biopharmaceuticals, Inc. January 2020 SMD-US-003644
Patient With Carcinoid Syndrome
Dr. Daneng Li, co-director of the neuroendocrine tumor program at City of Hope National Medical Center, offers his expertise and insight on diagnosis, treatment, and dietary practices for a patient with carcinoid syndrome. Patient on this episode is an actor, and represents a hypothetical case. Dr. Li is a paid consultant for Ipsen.
©2019 Ipsen Biopharmaceuticals, Inc. May 2019. SMD-US-002859
Patient With Midgut NET
Dr. Jonathan Strosberg, associate professor at Moffitt Cancer Center, discusses a hypothetical patient with symptomatic carcinoid midgut NET. Dr. Strosberg provides his specific insights on practice considerations for patients having disease progression. Patient on this episode is an actor, and represents a hypothetical case. Dr. Strosberg is a paid consultant for Ipsen. ©2019 Ipsen Biopharmaceuticals, Inc. May 2019. SMD-US-002964
Patient with Pancreatic NET
Dr. Andrew Hendifar, medical oncology lead for the Gastrointestinal Disease Research Group at Cedars-Sinai Medical Center, discusses a hypothetical patient with nonfunctional pancreatic NET. Dr. Hendifar provides practice pointers on disease presentation, tumor characteristics, diagnosis, and a 1st-line treatment option. Patient perspectives on this episode are voiced by actors, and represent hypothetical cases. Dr. Hendifar is a paid consultant for Ipsen. © 2020 Ipsen Biopharmaceuticals, Inc. April 2020. SMD-US-003939